Cancer NetworkOriginal article
<![CDATA[Daratumumab Combo Sets New OS Benchmark in Transplant-Ineligible NDMM]]>
Phase 3positivedaratumumabPositive
AI Analysis
Summary
Final analysis of the phase 3 MAIA trial demonstrated that daratumumab-based combination therapy achieved a median overall survival of 90.3 months in transplant-ineligible newly diagnosed multiple myeloma patients, establishing a new efficacy benchmark for this patient population.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Final analysis of MAIA trial showed median overall survival of 90.3 months in transplant-ineligible NDMM patients
Importance:7/10
Sentiment:
0.75
multiple myelomadaratumumabPhase 3MAIA trialoverall survival
Related Companies
Read the original article
Published by Cancer Network on August 27, 2026 6:00 PM